PAI
SGMT icon

Palo Alto Investors’s Sagimet Biosciences SGMT Stock Holding History

Palo Alto Investors’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.93M Buy
+250,000
New +$1.7M 0.27% 38

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Palo Alto Investors's SGMT Position: Q2 2026 in Review

Palo Alto Investors opened a new position in Sagimet Biosciences (SGMT) in Q2 2026: 250,000 shares worth $1.93M. The stake represents 0.27% of the portfolio and ranks #38 among its holdings.

122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Palo Alto Investors held 250,000 shares of Sagimet Biosciences worth $1.93M as of Q2 2026.
  • Sagimet Biosciences was a new Palo Alto Investors position in Q2 2026.
  • Sagimet Biosciences made up 0.27% of Palo Alto Investors's portfolio in Q2 2026, its #38 holding.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Palo Alto Investors's 13F filing for Q2 2026, filed 17 Aug 2026.